Sanara MedTech Inc. (SMTI)

Market Cap	294.40M
Revenue (ttm)	78.06M
Net Income (ttm)	-8.36M
Shares Out	8.74M
EPS (ttm)	-0.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,520
Open	31.21
Previous Close	31.59
Day's Range	31.21 - 33.87
52-Week Range	26.00 - 43.25
Beta	1.53
Analysts	Buy
Price Target	44.00 (+30.64%)
Earnings Date	Nov 12, 2024

About SMTI

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and pa...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1982
• Employees: 108
• Stock Exchange: NASDAQ
• Ticker Symbol: SMTI
• Website: https://sanaramedtech.com

Financial Performance

In 2023, Sanara MedTech's revenue was $64.99 million, an increase of 41.77% compared to the previous year's $45.84 million. Losses were -$4.30 million, -45.79% less than in 2022.

Analyst Forecast

According to one analyst, the rating for SMTI stock is "Buy" and the 12-month stock price forecast is $44.0.

Price Target

$44.0

(30.64% upside)

Analyst Consensus: Buy